Congratulations longs. It came a day earlier than expected by management. Target market now increased from 135,000 patients with burns and soft tissue to 645,000 patients annually, not including international expansion which will be announced in Q4. Originally, just 25,000 patients was the target market with burns. We’re looking at a market size increase of 25.8 times by January 2025, where burns and soft tissue will be breakeven by then according to CEO expectations.
This CEO appears trustworthy thus far hitting revenue guidance in Q1 and both FDA approvals. Looking forward to expected Recell Go approval in 199 days then likely significantly increased guidance in February.
Congratulations longs. It came a day earlier than expected by...
-
- There are more pages in this discussion • 53 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.56 |
Change
0.180(5.33%) |
Mkt cap ! $250.9M | |||
| Open | High | Low | Value | Volume |
| $3.54 | $3.58 | $3.48 | $1.596M | 452.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2865 | $3.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.57 | 5733 | 2 |
View Market Depth
| Last trade - 16.10pm 06/11/2024 (20 minute delay) ? |
| AVH (ASX) Chart |